GlobeNewswire by notified

MCH Group | Ad hoc announcement pursuant to Art. 53 LR | Extraordinary General of Meeting 28 September 2022

Share

Parameters of the proposed capital increase

With the publication and the mailing of the documents of the Extraordinary General Meeting on 28 September 2022, MCH Group announces the parameters of the announced rights offering and the proposed ordinary capital increase:

  • The Board of Directors intends to determine the maximum number of new shares to be offered in the rights offering in a way that, based on the subscription price, gross proceeds in the maximum amount of up to around CHF 80 million will be generated. Thereof CHF 68 million are backstopped by the Canton of Basel-Stadt and Lupa Systems.
  • In the invitation to the Extraordinary General Meeting published today, the Board of Directors proposes an ordinary capital increase through issuance of up to 18,586,688 new registered shares with subscription rights of the shareholders. The final proposed maximum number of new shares to be issued and the subscription price are expected to be determined and announced by the Board of Directors shortly before the Extraordinary General Meeting.

  • As a result of the capital increase, the shareholding of the Canton of Basel-Stadt and of Lupa Systems in the MCH Group is expected to increase to over 33 1/3% each. The Swiss Takeover Board (TOB) has granted the Canton of Basel-Stadt on 27 July 2022 an exemption from the obligation to make an offer pursuant to Article 135 of the Financial Market Infrastructure Act (FINMIA) for all listed equity securities of the company (so-called mandatory offer) if this threshold is exceeded. As the current articles of association of the MCH Group provide for a selective opting-up in favour of Lupa Systems and the persons acting in concert with it, exceeding the threshold of 33 1/3% in connection with the capital increase will also for Lupa Systems not trigger an obligation to make an offer under Article 135 FINMIA.

  • The conditions for the rights offering will be specified in a prospectus that the MCH Group will publish following the approval of the capital increase. The subscription rights shall be transferable and tradable.

  • The publication of the prospectus and the start of the rights exercise period shall take place promptly after the approval of the Extraordinary General Meeting of the proposed ordinary capital increase.

The Extraordinary General Meeting on 28 September 2022, will be held in written form. Shareholders can exercise their rights exclusively by appointing the independent proxy.

Contact:

MCH Group Ltd.
Secretary of the Board of Directors
Christian Jecker
+41 58 206 22 52
christian.jecker@mch-group.com

Disclaimer / Forward-looking statements
This document constitutes neither an offer nor an invitation to purchase or invest in securities of MCH Group Ltd. or one of its group companies. This document is neither a prospectus within the meaning of the Financial Services Act («FINSA») nor a prospectus according to any other legislation or regulation. Copies of this document may not be sent to, distributed in or sent from countries where this is prohibited by law. A decision to participate in the capital increase with subscription rights of MCH Group Ltd., which will be submitted to the vote of the Extraordinary General Meeting of MCH Group Ltd. on 28 September 2022, must be taken exclusively on the basis of a prospectus approved by a review body in accordance with Art. 51 FINSA, which will be published by MCH Group Ltd. for this purpose, and not on the basis of this document. Copies of such a prospectus will be available free of charge from the time of its publication.
This document and the information contained herein is not for publication or distribution into the United States of America (the «United States») and should not be distributed or otherwise transmitted into the United States or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended, or the «Securities Act») or publications with a general circulation in the United States. This document does not constitute an offer or invitation to subscribe for or to purchase any securities in the United States. The securities mentioned herein have not been and will not be registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. This document does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States or in any other jurisdiction.
Any offer of securities referred to herein, if and when made in member states of the European Economic Area («EEA»), will only be addressed to and directed to «qualified investors» within the meaning of Article 2(e) of the Prospectus Regulation («Qualified Investors»). For these purposes, the expression «Prospectus Regulation» means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, and includes any relevant delegated regulations. Any offer of securities referred to herein will be made pursuant to exemptions under the Prospectus Regulation from the requirement to produce a prospectus in connection with offers of securities.
For readers in the United Kingdom, this announcement is only being distributed to and is only directed at qualified investors within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 who are also (A) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the «FSMA Order») or (B) high net worth entities falling within Article 49(2)(a) to (d) of the FSMA Order (all such persons being referred to as «relevant persons»). Any securities referred to herein are expected to only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye